cash charg chang warrant valu
posit ride market growth tailwind
mdt recent report juli diabet result combin
perform well suggest strong underli us insulin
pump market rais us insulin market growth outlook high-singl
digit low-doubl digit also dovetail recent endocrinologist
survey work august link believ well suit captur
benefit acceler given pipelin basal-iq low-glucos suspend control-
iq hybrid close loop compani downsiz sport pump sport
expect learn timelin investor analyst day
clinic trial expect begin estim pt rise up
strong market strength new technolog introduct across diabet
pump cgm tide appear lift mani boat follow solid
us pump estim market grow
given momentum new product introduct ahead
look low-double-digit growth
driver bring next advanc insulin pump market
beyond basal-iq use cgm sensor input predict prevent
hypoglycem event roll control-iq hybrid closed-loop system
integr artifici pancrea algorithm cgm data also autom
correct bolus summer product posit well
share gainer view
sport tndm next-gener pump system size slim
includ short two-inch infus set worn abdomen/arm
sport on-pump touchscreen control dedic
control smartphon hold unit insulin cartridg
also potenti pipelin
sport sport design want greater discret
flexibl help captur multipl daili inject mdi patient
today new custom new pump therapi way
comparison custom formerli mdi sport trial expect
commenc launch anticip control-iq algorithm
rais estim up market growth assumpt rais
sale estim ep estim
also rise recent debt repay rais near/long-term estim
recent peer multipl expans price target rise price
target impli ev/sal in-lin forward ev/sal high-
inc medic
devic compani user-centr
design
develop commerci
patient
analyst certif import disclosur see disclosur
sever new opportun includ exit
larg competitor anima ramp new replac
cycl launch begin pipelin
summer control iq summer intern
launch track believ well posit
ramp intern distributor announc
agreement former anima distributor solid
us pump volum growth compound-annual-growth-rate exclud pump
increas captur potenti replac patient reach
gross margin reach
launch basal iq system august
roll fda submiss control iq system
approv control iq
quicker acceler new pump growth base autom
greater expect contribut anima
greater expect competit pressur particularli
failur reach gross margin long-term thu longer
expect move cash flow break-even
price target driven blend dcf peer multipl analysi target price impli ev/sal rais
compar previou ev/sal multipl incorpor rais near/long-term estim opportun continu
sale growth led compani pipelin tndm high-growth peer group multipl forward averag also expand
last price target updat dcf use weight averag cost capit wacc ebitda
termin growth
competit new product rollout regulatori approv gross margin/opex leverag requir reach cash flow break-even
interest incom
sourc oppenheim estim compani report
footnot includ non-cash charg chang fair valu seri a/b warrant oct financ
stock price compani mention report
